Xilis

Xilis is a Durham, North Carolina-based biotechnology company pioneering next-generation ex-vivo technologies to accelerate and de-risk drug development, from initial discovery through clinical trials, and to guide precision cancer therapy.

We specialize in developing innovative solutions utilizing organoids, precision medicine, and artificial intelligence to revolutionize the way cancer is treated. Our core focus is on creating robust and reliable models for predicting drug efficacy and patient response, significantly reducing the time and cost associated with traditional research methods.

Xilis is dedicated to advancing oncology and cancer research by providing cutting-edge tools for tissue engineering, microfluidics, and screening. We are committed to transforming the landscape of drug development and ultimately improving patient outcomes through personalized therapies.

Founded in 2019, Xilis currently employs a team of 15 experts and is rapidly expanding its capabilities in ex vivo technology and machine learning.